

Antihypertensivum	$C_{\min}$ waarmee Concentratie Ratio wordt berekend	Dosering waarvoor $C_{\min}$ is afgeleid	Halfwaardetijd	Literatuur
Acebutolol	200 µg/L	2 x daags 400 mg	Kort (3 uur)	[1]
Aliskiren	5 µg/L	1 x daags 150 mg	Lang (40 uur)	[2]
Amlodipine	7 µg/L	1 x daags 5 mg	Lang (35-50 uur)	[3]
Atenolol	100 µg/L	1 x daags 100 mg	Gemiddeld (6-9 uur)	[4]
Barnidipine	Positief/negatief	1 x daags 10 mg (MGA)	Lang (20 uur)	[5]
Bisoprolol	10 µg/L	1 x daags 20 mg	Gemiddeld (10-12 uur)	[6]
Bumetanide	1 µg/L	$C_{\min} = C_{12h}$ onder 1 x daags 2 mg	Kort (0.75-2.5 uur)	[7]
Candesartan	12 µg/L	1x daags 12 mg	Gemiddeld (9 uur)	[8]
Canrenon (= metaboliet spironolacton)	100 µg/L	1 x daags 200 mg	Lang (10-35 uur)	[9]
Captopril	4 µg/L	3 x daags 25 mg	Kort (2 uur)	[10]
Carvedilol	10 µg/L	2 x daags 25 mg	Gemiddeld (6-10 uur)	[11]
Celiprolol	20 µg/L	1x daags 200 mg	Kort (5-6 uur)	[12]
Chloortalidon	10 µg/L	1 x daags 12,5 mg	Lang (50 uur)	[13]
Diltiazem	10 µg/L	1 x daags 120 mg	Kort (4–8 uur)	[14]
Doxazosine	10 µg/L	1 x daags 4 mg MGA	Lang (16-30 uur)	[15]

Antihypertensivum	$C_{\min}$ waarmee Concentratie Ratio wordt berekend	Dosering waarvoor $C_{\min}$ is afgeleid	Halfwaardetijd	Literatuur
Enalapriilaat	1 µg/L	1 x daags 10 mg	Gemiddeld (11 uur)	[16]
Epleneron	20 µg/L	1 x daags 25 mg	Kort (3–6 uur)	[17]
Felodipine	1 µg/L	1 x daags 5 mg	Lang (25 uur)	[18]
Fosinopriilaat	8 µg/L	1 x daags 10 mg	Gemiddeld (11-14 uur)	[19]
Furosemide	3 µg/L	1 x daags 20 mg	Kort (0,5-1 uur)	[20]
Hydrochloorthiazide	10 µg/L	1 x daags 25 mg	Gemiddeld (10-13 uur)	[3]
Indapamide	30 µg/L	1 x daags 1,5 mg	Lang (14-24 uur)	[21]
Irbesartan	20 µg/L	1 x daags 50 mg	Gemiddeld (11–15 uur)	[22]
Labetalol	50 µg/L	2 x daags 200 mg	Kort (4 uur)	[23]
Lercanidipine	0,1 µg/L	1 x daags 20 mg	Gemiddeld (8-10 uur)	[24]
Lisinopril	2 µg/L	1 x daags 2.5 mg	Gemiddeld (12-13 uur)	[25]
Losartan_Carboxylic_acid	1 µg/L	1 x daags 100 mg	Gemiddeld (6–9 uur)	[26]
Methyldopa	100 µg/L	1 x daags 250 mg	Kort (2 uur)	[27]
Metoprolol	5 µg/L	1 x daags 50 mg metoprolol succinaat MGA	Kort (3–4 uur)	[28]
Minoxidil	0,3 µg/L	2 x daags 2.5 mg	Kort (4 uur)	[29]
Moxonidine	0,2 µg/L	$C_{\min} = C_{12h}$ onder 1 x daags 0,2 mg	Kort (2 uur)	[30]

Antihypertensivum	$C_{\min}$ waarmee Concentratie Ratio wordt berekend	Dosering waarvoor $C_{\min}$ is afgeleid	Halfwaardetijd	Literatuur
Nebivolol	0,05 µg/L	1 x daags 10 mg	Gemiddeld (10-50 uur)	[31]
Nifedipine	5 µg/L	4 x daags 10 mg immediate release	Capsule kort (2–3 uur) Tablet retard 6-11 uur	[32]
Olmesartan	20 µg/L	1 x daags 20 mg	Gemiddeld (10–15 uur)	[33]
Perindopriilaat	1,5 µg/L	1 x daags 4 mg	Lang (17–25 uur)	[34]
Propranolol	20 µg/L	3 x daags 80 mg	Kort (3–6 uur); MGA preparaat 8-20 uur	[35]
Quinapriilaat	10 µg/L	1 x daags 80 mg	Kort (2-3 uur)	[36]
Ramipriilaat	1 µg/L	1x daags 5 mg	Gemiddeld (13-17 uur)	[37]
Sotalol	125 µg/L	2 x daags 40 mg	Gemiddeld (10–20 uur)	[38]
Spironolacton: zie canrenon				
Telmisartan	8 µg/L	1 x daags 40 mg	Lang (20 uur)	[39]
Triamteren	1 µg/L	1 x daags 25 mg	Kort (4 uur)	[40]
Valsartan	200 µg/L	1 x daags 320 mg	Kort (6 uur)	[3]
Verapamil	10 µg/L	3 x daags 80 mg	Kort (2-8 uur)	[41]

Literatuur:

1. Martin MA, Phillips FC, Tucker GT, et al. Acebutolol in hypertension: relationships between drug concentration and effects. *Eur J Clin Pharmacol.* 1978;14:383-390.
2. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. *J Clin Pharmacol.* 2008;48:1323-1338.
3. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. *Int J Clin Pract.* 2006;60:1343-56.
4. Kirch W, Görg KG. Clinical pharmacokinetics of atenolol--a review. *Eur J Drug Metab Pharmacokinet.* 1982;7:81-91.
5. Malhotra, H.S., Plosker, G.L. Barnidipine. *Drugs* 2001;61: 989–996
6. Leopold G, Pabst J, Ungethüm W, Bühring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. *J Clin Pharmacol.* 1986;26: 616-621.
7. Dinesh S. Patel, Naveen Sharma, Mukesh C. Patel, et al. Application of a rapid and sensitive liquid chromatography–tandem mass spectrometry method for determination of bumetanide in human plasma for a bioequivalence study, *Journal of Pharmaceutical and Biomedical Analysis* 2012;66:365-370.
8. Gleiter, C.H., Mörike, K.E. Clinical Pharmacokinetics of Candesartan. *Clin Pharmacokinet* 41, 7–17 (2002).
9. Karim A, Zagarella J, Hutsell TC, et al. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels. *Clin Pharmacol Ther.* 1976;19:177-182.
10. Cody RJ, Covit A, Schaer G, et al. Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. *Am Heart J.* 1982;104:1180-1183.
11. Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. *Am J Cardiol.* 2006;98:17L-26L.
12. Norris RJ, Lee EH, Muirhead D, Sanders SW. A pharmacokinetic evaluation of celiprolol in healthy elderly volunteers. *J Cardiovasc Pharmacol.* 1986;8 Suppl 4: S91-S92.
13. Tsai MC, Wu J, Kupfer S, Vakilynejad M. Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. *J Clin Pharmacol.* 2016;56:988-998.
14. Boyd RA, Chin SK, Don-Pedro O, et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. *Clin Pharmacol Ther.* 1989;46:408-419.
15. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. *Br J Clin Pharmacol.* 1999;48:678-687.
16. Arafat T, Awad R, Hamad M, et al. Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. *J Clin Pharm Ther.* 2005;30:319-328.
17. Ravis WR, Reid S, Sica DA, et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. *J Clin Pharmacol.* 2005;45:810-821.
18. Xiang Q, Li C, Zhao X, et al. The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. *J Clin Pharm Ther.* 2017;42:345-349.
19. Shionoiri, H., Naruse, M., Minamisawa, K. et al. Fosinopril. *Clin-Pharmacokinet* 1997;32:460–480
20. Vaidyanathan S, Bartlett M, Dieterich HA, et al. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. *Cardiovasc Ther.* 2008;26:238-246.
21. Wang TH, Hsiong CH, Ho HT, et al. Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects. *AAPS J.*

2014;16:206-213.

22. Vachharajani NN, Shyu WC, Smith RA, et al. The effects of age and gender on the pharmacokinetics of irbesartan. *Br J Clin Pharmacol* 1998;46:611-613.
23. Chung M, Leitz FH, Maier G, et al. Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. *J Clin Pharmacol*. 1986;26:248-252.
24. Jabor VA, Coelho EB, Lanchote VL. Enantioselective pharmacokinetics of lercanidipine in healthy volunteers. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2004;813:343-346.
25. Beermann B, Till AE, Gomez HJ, et al. Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. *Biopharm Drug Dispos*. 1989;10:397-409.
26. Das AK, Dhanure S, Savalia AK, et al. Human bioequivalence evaluation of two losartan potassium tablets under fasting conditions. *Indian J Pharm Sci*. 2015;77:190-195.
27. Valizadeh H, Nemati M, Hallaj-Nezhadi S, et al. Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. *Arzneimittelforschung*. 2010;60:607-611.
28. Sarkar AK, Ghosh D, Das A, et al. Simultaneous determination of metoprolol succinate and amlodipine besylate in human plasma by liquid chromatography-tandem mass spectrometry method and its application in bioequivalence study. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2008;873:77-85.
29. Carrum G, Abernethy DR, Sadhukhan M, Wright CE 3rd. Minoxidil analysis in human plasma using high-performance liquid chromatography with electrochemical detection. Application to pharmacokinetic studies. *J Chromatogr*. 1986;381:127-135.
30. He MM, Abraham TL, Lindsay TJ, et al. Metabolism and disposition of the antihypertensive agent moxonidine in humans. *Drug Metab Dispos*. 2003;31:334-42.
31. Neves DV, Lanchote VL, Moysés Neto M, et al. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. *Br J Clin Pharmacol*. 2016;82:83-91.
32. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. *Drug Metab Dispos*. 1996;24:1121-1123.
33. Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. *Clin Drug Investig*. 2006;26:29-34.
34. Li Q, Hao Z, Yu Y, Tang Y. Bioequivalence study of two perindopril tert-butylamine tablet formulations in healthy Chinese subjects under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial. *Biomed Pharmacother*. 2021;135:111221.
35. Salem SA, McDevitt DG. Central effects of single oral doses of propranolol in man. *Br J Clin Pharmacol*. 1984;17:31-36.
36. Vertes V, Haynie R. Comparative pharmacokinetics of captopril, enalapril, and quinapril. *Am J Cardiol*. 1992;69:8C-16C.
37. Verho M, Luck C, Stelter WJ, et al. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. *Curr Med Res Opin*. 1995;13:264-273.
38. Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. *Am J Cardiol*. 1990;65:12A-21A; discussion 35A-36A.
39. Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. *J Clin Pharmacol*. 2000;40:1323-1330.
40. Brodie RR, Chasseaud LF, Darragh A, et al. Bioavailability of bemetizide and triamterene from a combination formulation. *Biopharm Drug Dispos*. 1982;3:361-370.
41. Mooy J, Schols M, v Baak M, et al. Pharmacokinetics of verapamil in patients with renal failure. *Eur J Clin Pharmacol*. 1985;28:405-410.